Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 2,493 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $53.99, for a total value of $134,597.07. Following the completion of the transaction, the chief operating officer now owns 198,047 shares in the company, valued at $10,692,557.53. This trade represents a 1.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Akero Therapeutics Stock Performance
Akero Therapeutics stock traded up $2.06 during trading hours on Friday, hitting $55.62. The stock had a trading volume of 2,224,332 shares, compared to its average volume of 1,009,425. The company has a 50-day moving average of $43.96 and a two-hundred day moving average of $40.36. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market cap of $4.43 billion, a PE ratio of -14.83 and a beta of -0.16. Akero Therapeutics, Inc. has a fifty-two week low of $21.02 and a fifty-two week high of $58.40.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of ($1.01) by $1.91. On average, equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.
Institutional Investors Weigh In On Akero Therapeutics
Several large investors have recently modified their holdings of AKRO. Rhumbline Advisers grew its stake in shares of Akero Therapeutics by 1.3% in the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company's stock valued at $2,940,000 after purchasing an additional 1,310 shares during the period. Handelsbanken Fonder AB grew its stake in shares of Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock valued at $584,000 after purchasing an additional 1,000 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Akero Therapeutics in the 4th quarter valued at approximately $320,000. Charles Schwab Investment Management Inc. grew its stake in shares of Akero Therapeutics by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock valued at $15,042,000 after purchasing an additional 8,096 shares during the period. Finally, AlphaQuest LLC grew its stake in shares of Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after purchasing an additional 8,147 shares during the period.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on AKRO shares. Bank of America boosted their price target on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. HC Wainwright boosted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Citigroup cut their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Akero Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $82.50.
Check Out Our Latest Analysis on Akero Therapeutics
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Further Reading
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
